Adaptyx wins FDA Breakthrough Device tag for cortisol monitor

Adaptyx Biosciences, a Stanford University spinout, has received FDA Breakthrough Device Designation for its continuous cortisol monitoring device and has been accepted into the agency's Total Product Life Cycle Advisory Programme (TAP). The Menlo Park-based company said both recognitions will accelerate its path to regulatory clearance for a wearable that can measure cortisol continuously in dermal interstitial fluid.

The device is intended to support diagnosis and management of conditions characterised by abnormal cortisol levels, including Cushing syndrome, mild autonomous cortisol secretion, adrenal insufficiency, difficult-to-control type 2 diabetes, and resistant hypertension. Breakthrough Device Designation gives Adaptyx expedited FDA review and more frequent structured interactions with the agency. TAP acceptance pairs the company with dedicated FDA review teams and provides early access to payers and provider organisations, allowing regulatory and reimbursement strategy to be developed in parallel.

The technology

Adaptyx's platform departs from conventional enzyme-mediated biosensing, which is limited to a narrow set of analytes such as glucose and ketone bodies. Instead, the company uses programmable DNA-based molecular switches: engineered oligonucleotides that change conformation and generate an electrical signal upon binding a target molecule. The approach extends continuous measurement to a much broader range of analytes, including hormones, electrolytes, and pharmaceutical compounds. The technology is grounded in more than 18 years of continuous molecular biosensing research from Stanford laboratories and is protected by nine exclusively licensed Stanford patents, with 18 additional filings made since the company's founding.

Daniel Grossman, Chief Medical and Business Officer at Adaptyx, said the clinical unmet need is substantial. "Patients with suspected and known cortisol-related disorders, and the clinicians who diagnose and manage them, have not seen a meaningful change in diagnostic technology in many years," he said. "These adrenal conditions are chronically underdiagnosed and a challenge to manage because patients and clinicians have relied on single-time-point blood draws to characterise a hormone that fluctuates throughout the day."

Market context and regulatory read-across

The continuous glucose monitoring market, led by Dexcom and Abbott's FreeStyle Libre, has demonstrated that wearable biosensing can shift clinical practice across a chronic-disease population. Cortisol monitoring represents a significantly smaller addressable population at present, but clinicians and investors have noted the potential for expansion into stress physiology, sleep medicine, and performance health if the technology proves robust in dermal interstitial fluid at physiologically relevant concentrations.

FDA Breakthrough Device Designation has become an increasingly sought-after milestone in the diagnostics and device sectors since the programme's formalisation under the 21st Century Cures Act. A number of wearable biosensing companies are pursuing comparable continuous hormone monitoring platforms, making early FDA engagement and the IP estate around the DNA-switch approach important competitive factors for Adaptyx.

The company has raised $23 million in seed financing to date. With TAP acceptance now confirmed, the near-term priority is advancing a pivotal clinical programme; investors and clinical partners will be watching for the first substantive data from that programme as the key inflection point for the cortisol monitor's commercial viability.